CA2592292A1 - Sustained delivery of pdgf using self-assembling peptide nanofibers - Google Patents

Sustained delivery of pdgf using self-assembling peptide nanofibers Download PDF

Info

Publication number
CA2592292A1
CA2592292A1 CA002592292A CA2592292A CA2592292A1 CA 2592292 A1 CA2592292 A1 CA 2592292A1 CA 002592292 A CA002592292 A CA 002592292A CA 2592292 A CA2592292 A CA 2592292A CA 2592292 A1 CA2592292 A1 CA 2592292A1
Authority
CA
Canada
Prior art keywords
seq
peptides
pdgf
self
biologically compatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002592292A
Other languages
English (en)
French (fr)
Inventor
Richard T. Lee
Patrick Hsieh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2592292A1 publication Critical patent/CA2592292A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA002592292A 2005-01-04 2005-12-29 Sustained delivery of pdgf using self-assembling peptide nanofibers Abandoned CA2592292A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64099805P 2005-01-04 2005-01-04
US60/640,998 2005-01-04
US70231805P 2005-07-26 2005-07-26
US60/702,318 2005-07-26
PCT/US2005/046768 WO2006073889A2 (en) 2005-01-04 2005-12-29 Sustained delivery of pdgf using self-assembling peptide nanofibers

Publications (1)

Publication Number Publication Date
CA2592292A1 true CA2592292A1 (en) 2006-07-13

Family

ID=36648006

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002592292A Abandoned CA2592292A1 (en) 2005-01-04 2005-12-29 Sustained delivery of pdgf using self-assembling peptide nanofibers

Country Status (6)

Country Link
US (1) US7429567B2 (enExample)
EP (1) EP1833504A4 (enExample)
JP (1) JP2008526749A (enExample)
AU (1) AU2005323062A1 (enExample)
CA (1) CA2592292A1 (enExample)
WO (1) WO2006073889A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4023240A1 (en) * 2004-07-06 2022-07-06 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof
US9162005B2 (en) * 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US9327010B2 (en) 2005-04-25 2016-05-03 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
CN101472620A (zh) 2006-04-25 2009-07-01 麻省理工学院 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法
EP2502628B1 (en) * 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US8022178B2 (en) * 2006-09-26 2011-09-20 Massachusetts Institute Of Technology Modified self-assembling peptides
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9187517B2 (en) 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
DK2089047T3 (da) * 2006-12-11 2013-02-18 3D Matrix Inc Sammensætninger og fremgangsmåder til beskyttelse og regenerering af hjerte-væv
DK2146733T3 (da) * 2007-03-14 2021-01-11 Arch Biosurgery Inc Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
EP2345433B1 (en) 2008-10-06 2017-03-01 3-D Matrix, Ltd. Tissue plug
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
US20110117195A1 (en) * 2009-11-18 2011-05-19 National Cheng Kung University Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
JP5732691B2 (ja) * 2010-01-14 2015-06-10 学校法人同志社 インスリン製剤
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
US10662234B2 (en) 2011-06-07 2020-05-26 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004467A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Selective cartilage therapy
WO2014004465A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
JP6389170B2 (ja) 2012-07-06 2018-09-12 スリーディー マトリックス， エルティーディー３−Ｄ Ｍａｔｒｉｘ， Ｌｔｄ． ペプチド溶液のためのフィル−フィニッシュ過程
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
US10130735B2 (en) * 2012-09-21 2018-11-20 Technologias Avanzadas Inspiralia S.L. Scaffold for cardiac patch
CN105658252A (zh) 2013-08-22 2016-06-08 阿奇生物外科有限公司 用于控制流体移动的可植入网状物
AU2014327234B2 (en) 2013-09-25 2019-02-21 Credentis Ag Dental care product for tooth whitening
EP2853256A1 (en) 2013-09-25 2015-04-01 Credentis AG Dental care product for tooth whitening
JP6684719B2 (ja) 2014-03-10 2020-04-22 株式会社スリー・ディー・マトリックス ペプチド組成物の滅菌および濾過
ES2712608T3 (es) 2014-03-10 2019-05-14 3 D Matrix Ltd Péptidos autoensamblantes para el tratamiento de las bullas pulmonares
CA2939696C (en) 2014-03-10 2023-01-10 3-D Matrix, Ltd. Self-assembling peptide compositions
CN104497107B (zh) * 2014-12-08 2017-09-19 重庆医科大学 一种自组装短肽及其在细胞三维培养中的应用
CN104693277B (zh) * 2015-03-26 2018-02-13 罗忠礼 一种自组装短肽及其在细胞三维培养中的应用
CN105148289B (zh) * 2015-09-30 2018-10-09 南京中医药大学 一种两亲性寡聚多肽药物结合物
CN105288653B (zh) * 2015-11-19 2018-10-09 南京中医药大学 一种两亲性寡聚多肽药物结合物
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
EP3248591A1 (en) 2016-05-24 2017-11-29 Credentis AG Method and product for caries treatment
EP3248590A1 (en) 2016-05-24 2017-11-29 Credentis AG Personal dental care product for caries treatment
EP3723726A1 (en) 2017-12-15 2020-10-21 3-D Matrix, Ltd. Surfactant peptide nanostructures and uses in drug delivery
WO2020171161A1 (ja) * 2019-02-20 2020-08-27 国立大学法人東京農工大学 自己組織化ペプチド
EP3831360A1 (en) 2019-12-04 2021-06-09 Credentis AG Personal dental care product for preventing demineralisation
US11154470B1 (en) 2020-07-31 2021-10-26 vVardis AG Anti-inflammatory and senolytic dental care product with tooth whitening characteristics
CN114181295B (zh) * 2021-12-15 2023-07-04 湖南大学 一种多肽衍生物及其用途、水凝胶及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
EP0697883A1 (en) * 1993-04-29 1996-02-28 Washington University Use of platelet-derived growth factor to improve collateral circulation
EP0832269A1 (en) * 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
WO2001035932A2 (en) * 1999-11-18 2001-05-25 The Regents Of The University Of Michigan Sustained drug delivery from structural matrices
ATE419333T1 (de) * 2001-02-06 2009-01-15 Massachusetts Inst Technology Peptidgerüstverkapselung von gewebszellen und verwendungen davon
US7449180B2 (en) * 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
CA2440387A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
WO2003006043A1 (en) * 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
US20040105839A1 (en) * 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
US20030139333A1 (en) * 2002-01-18 2003-07-24 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis
WO2003096972A2 (en) * 2002-05-13 2003-11-27 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
WO2004007683A2 (en) * 2002-07-15 2004-01-22 Massachusetts Institute Of Technology Cellular reprogramming in peptide hydrogel and uses thereof
JP2004115413A (ja) * 2002-09-25 2004-04-15 Yasuhiko Tabata 冠状動脈狭窄または閉塞治療用徐放性製剤
WO2004045531A2 (en) * 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
DK1636250T3 (en) * 2003-06-25 2016-02-22 Massachusetts Inst Technology SELF-ORGANIZING PEPTIDES, CONTAINING MODIFICATIONS, AND APPLICATIONS THEREOF
EP4023240A1 (en) * 2004-07-06 2022-07-06 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof

Also Published As

Publication number Publication date
WO2006073889A2 (en) 2006-07-13
US20060148703A1 (en) 2006-07-06
WO2006073889A3 (en) 2007-06-14
US7429567B2 (en) 2008-09-30
JP2008526749A (ja) 2008-07-24
EP1833504A4 (en) 2009-08-12
AU2005323062A1 (en) 2006-07-13
EP1833504A2 (en) 2007-09-19

Similar Documents

Publication Publication Date Title
US7429567B2 (en) Sustained delivery of PDGF using self-assembling peptide nanofibers
Hsieh et al. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers
EP2076290B1 (en) Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US20110117195A1 (en) Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
US20060088510A1 (en) Targeted delivery of biological factors using self-assembling peptide nanofibers
US9938320B2 (en) Peptides for promoting angiogenesis and use thereof
JP2013155193A (ja) Ｆｇｆの脈管形成的に有効な単位用量および投与方法
JP2010503710A5 (enExample)
ES2600806T3 (es) Procedimientos para tratar o prevenir el daño tisular causado por aumento de flujo sanguíneo
JP6339231B2 (ja) 線維症性疾患の処置のためのＴｒａｉｌレセプターアゴニスト
Wang et al. Cascaded bio-responsive delivery of eNOS gene and ZNF 580 gene to collaboratively treat hindlimb ischemia via pro-angiogenesis and anti-inflammation
RS60181B1 (sr) Terapeutska upotreba morfogenetskih proteina kosti
JP2012530735A (ja) 眼疾患の治療におけるＣＤ４４ｖ６の使用
CN114344481A (zh) 一种多肽自组装纳米药物及其制备方法和应用
AU2006308989A1 (en) Novel protein transduction domains and uses therefor
Yun et al. N-Terminal modification of the tetrapeptide Arg-Leu-Tyr-Glu, a vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist, improves antitumor activity by increasing its stability against serum peptidases
US20030228283A1 (en) Preventing secondary lymphedema with VEGF-D DNA
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
WO2003080103A1 (en) Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents
JP2025534734A (ja) 心筋細胞を保存及び保護し、心損傷後の心筋線維化を軽減する方法
US20220257711A1 (en) PEPTOID-PEPTIDE HYBRID, NMEG-aCGRP, AND ITS USE IN CARDIOVASCULAR DISEASES
JP5734856B2 (ja) 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用
CN109734779B (zh) 一种靶向Tie-1的多肽及其应用
Zhao et al. Salvianolic acid B, a novel GLS1 accelerator, alleviates defective endothelial glutaminolysis contributes to impaired angiogenesis and poor ischemic tissue repair in diabetes
CN120983639A (zh) 一种基于多肽修饰的寡核苷酸纳米递送体系及其应用

Legal Events

Date Code Title Description
FZDE Discontinued